Bioresorbable Scaffolds versus Metallic Stents in Routine PCI

Cardiac Arrest or DeathMyocardial InfarctionThrombosis and StrokeTherapy and Intervention

Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial

Lancet.

Brilakis ES, Edson R, Bhatt DL, Goldman S, Holmes DR Jr, Rao SV, Shunk K, Rangan BV, Mavromatis K, Ramanathan K, Bavry AA, Garcia S, Latif F, Armstrong E, Jneid H, Conner TA, Wagner T, Karacsonyi J, Uyeda L, Ventura B, Alsleben A, Lu Y, Shih MC, Banerjee S; DIVA Trial Investigators

doi: 10.1016/

Therapy and Intervention

Myocardial Blood Flow and Coronary Flow Reserve During 3 Years Following Bioresorbable Vascular Scaffold Versus Metallic Drug-Eluting Stent Implantation: The VANISH Trial

JACC Cardiovasc Interv.

Stuijfzand WJ, Schumacher SP, Driessen RS, Lammertsma AA, Bakker AL, Rijnierse MT, van Rossum AC, van de Ven PM, Nap A, Appelman Y, van Royen N, van Leeuwen MA, Lemkes JS, Raijmakers PG, Knaapen P

doi: 10.1016/j.jcin.2019.03.004.

Cardiac Arrest or DeathAtrial FibrillationMyocardial InfarctionThrombosis and StrokeTherapy and Intervention

Safety and Efficacy of Polymer-Free Biolimus A9-Coated Versus Bare-Metal Stents in Orally Anticoagulated Patients: 2-Year Results of the LEADERS FREE Oral Anticoagulation Substudy

JACC Cardiovasc Interv.

Carrié D, Menown I, Oldroyd K, Copt S, Talwar S, Maillard L, Morice MC, Teik LS, Lang I, Urban P

doi: 10.1016/j.jcin.2017.05.033.

Heart, Artery and Coronary DiseasesTherapy and Intervention

Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial

Lancet.

Kandzari DE, Mauri L, Koolen JJ, Massaro JM, Doros G, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R; BIOFLOW V Investigators

doi: 10.1016/S0140-

Myocardial Infarction

Magnesium-Based Resorbable Scaffold versus Permanent Metallic SirolimusEluting Stent in Patients with ST-Segment Elevation Myocardial Infarction: The MAGSTEMI Randomized Clinical Trial

Circulation.

Sabaté M, Alfonso F, Cequier A, Romaní S, Bordes P, Serra A, Iñiguez A, Salinas P, García Del Blanco B, Goicolea J, Hernández-Antolín R, Cuesta J, Gómez-Hospital JA, Ortega-Paz L, Gomez-Lara J, Brugaletta S

doi: 10.1161/CIRCULATIONAHA.

Myocardial Infarction

Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial

PLoS One.

Schur N, Brugaletta S, Cequier A, Iñiguez A, Serra A, Jiménez-Quevedo P, Mainar V, Campo G, Tespili M, den Heijer P, Bethencourt A, Vazquez N, Valgimigli M, Serruys PW, Ademi Z, Schwenkglenks M, Sabaté M

doi: 10.1371/journal.pone.

Therapy and Intervention

Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial

Lancet.

Stone GW, Ellis SG, Gori T, Metzger DC, Stein B, Erickson M, Torzewski J, Williams J Jr, Lawson W, Broderick TM, Kabour A, Piegari G, Cavendish J, Bertolet B, Choi JW, Marx SO, Généreux P, Kereiakes DJ; ABSORB IV Investigators

doi: 10.1016/S0140-6736

Heart, Artery and Coronary Diseases

Diagnostic Accuracy of Coronary CT Angiography for the Evaluation of Bioresorbable Vascular Scaffolds

JACC Cardiovasc Imaging.

Collet C, Chevalier B, Cequier A, Fajadet J, Dominici M, Helqvist S, Van Boven AJ, Dudek D, McClean D, Almeida M, Piek JJ, Tenekecioglu E, Bartorelli A, Windecker S, Serruys PW, Onuma Y

doi: 10.1016/j.jcmg.2017.04.013.

Heart, Artery and Coronary DiseasesTherapy and Intervention

3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial

J Am Coll Cardiol.

Kereiakes DJ, Ellis SG, Metzger C, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW; ABSORB III Investigators

doi: 10.1016/j.jacc.2017.10.010.

Related content

Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial

Myocardial Blood Flow and Coronary Flow Reserve During 3 Years Following Bioresorbable Vascular Scaffold Versus Metallic Drug-Eluting Stent Implantation: The VANISH Trial

Safety and Efficacy of Polymer-Free Biolimus A9-Coated Versus Bare-Metal Stents in Orally Anticoagulated Patients: 2-Year Results of the LEADERS FREE Oral Anticoagulation Substudy

Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial

Magnesium-Based Resorbable Scaffold versus Permanent Metallic SirolimusEluting Stent in Patients with ST-Segment Elevation Myocardial Infarction: The MAGSTEMI Randomized Clinical Trial

Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial

Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial

Diagnostic Accuracy of Coronary CT Angiography for the Evaluation of Bioresorbable Vascular Scaffolds

3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial